Dynavax Technologies

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, founded in 1996. The company focuses on developing and commercializing vaccines and immunotherapies to protect against infectious diseases. Its flagship product, HEPLISAV-B, is a hepatitis B vaccine approved for adults, designed to prevent infection from all known subtypes of the virus. This vaccine utilizes CpG 1018, an adjuvant technology developed by Dynavax to enhance immune response, and is marketed primarily in the United States, with approvals in the European Union and Great Britain. Dynavax has a robust pipeline of vaccine candidates in clinical development, including a plague vaccine and an investigational vaccine for shingles prevention. The company serves a diverse customer base, including hospitals, clinics, and government agencies, with distribution through wholesalers and specialty distributors. Under the leadership of CEO Ryan Spencer, Dynavax has expanded its commercial presence and invested significantly in research and development, reporting revenues exceeding $415 million in 2023. The company maintains strategic collaborations to support vaccine development and global distribution efforts.